- Home
- APVO vs NVVE Comparison
APVO vs NVVE Comparison
Compare APVO & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- NVVE
- Stock Information
- Founded
- APVO 2016
- NVVE 1996
- Country
- APVO United States
- NVVE United States
- Employees
- APVO N/A
- NVVE N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- NVVE Oil Refining/Marketing
- Sector
- APVO Health Care
- NVVE Energy
- Exchange
- APVO Nasdaq
- NVVE Nasdaq
- Market Cap
- APVO 3.3M
- NVVE 3.7M
- IPO Year
- APVO N/A
- NVVE N/A
- Fundamental
- Price
- APVO $0.67
- NVVE $0.91
- Analyst Decision
- APVO Strong Buy
- NVVE
- Analyst Count
- APVO 1
- NVVE 0
- Target Price
- APVO $296.00
- NVVE N/A
- AVG Volume (30 Days)
- APVO 8.7M
- NVVE 108.7K
- Earning Date
- APVO 05-07-2025
- NVVE 05-13-2025
- Dividend Yield
- APVO N/A
- NVVE N/A
- EPS Growth
- APVO N/A
- NVVE N/A
- EPS
- APVO N/A
- NVVE N/A
- Revenue
- APVO N/A
- NVVE $5,286,229.00
- Revenue This Year
- APVO N/A
- NVVE $892.33
- Revenue Next Year
- APVO N/A
- NVVE N/A
- P/E Ratio
- APVO N/A
- NVVE N/A
- Revenue Growth
- APVO N/A
- NVVE N/A
- 52 Week Low
- APVO $0.60
- NVVE $0.82
- 52 Week High
- APVO $51.06
- NVVE $17.30
- Technical
- Relative Strength Index (RSI)
- APVO 30.74
- NVVE 30.94
- Support Level
- APVO $0.60
- NVVE $0.87
- Resistance Level
- APVO $0.80
- NVVE $0.99
- Average True Range (ATR)
- APVO 0.19
- NVVE 0.08
- MACD
- APVO 0.03
- NVVE 0.03
- Stochastic Oscillator
- APVO 6.97
- NVVE 41.09
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.